Monday, November 15, 2010 1:27:31 PM
DrF. you never mentioned that the initial 24 hours of damage are that significant that the lung tissue is beyond repair. Are you sure you can make that call? Seems like we'd need intimate knowledge about the mechanisms at hand. Dane, I did read it, but I want deeper information.
So from the study we can conclude FluCide is good at stopping the virus from spreading (initial spreading and second phase spreading(from infected cells). While Tamiflu, an alternative method, which prevents the infected cells from freeing new virus particles (thus focusses ONLY on preventing spreading from INFECTED cells). Remains interesting to see if both combined would be the even better approach. Though the health issues of TamiFlu might be unwanted.
Questions remaining:
What were the doses of nanoviricide / FluCide in previous experiments? (100mg/kg in this one...)
What are the "Other overt parameters of virus infection"?
When were the viral measurements taken? (were the done after death?)...
Guys, ask more questions and you'll learn more, thats all I'm doing. Be quick to listen, slow to answer. These are tough questions. bbl.
So from the study we can conclude FluCide is good at stopping the virus from spreading (initial spreading and second phase spreading(from infected cells). While Tamiflu, an alternative method, which prevents the infected cells from freeing new virus particles (thus focusses ONLY on preventing spreading from INFECTED cells). Remains interesting to see if both combined would be the even better approach. Though the health issues of TamiFlu might be unwanted.
Questions remaining:
What were the doses of nanoviricide / FluCide in previous experiments? (100mg/kg in this one...)
What are the "Other overt parameters of virus infection"?
When were the viral measurements taken? (were the done after death?)...
Guys, ask more questions and you'll learn more, thats all I'm doing. Be quick to listen, slow to answer. These are tough questions. bbl.
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
